Opus Genetics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Opus Genetics, a clinical-stage biopharmaceutical company, reported positive clinical trial results for its lead gene therapies, OPGx-LCA5 and OPGx-BEST1, alongside reduced net losses and increased cash reserves for fiscal year 2025.
NASDAQ
Opus Genetics provides an update on its financial standing, gene therapy pipeline advancements, and strategic partnerships in its annual 10-K filing.
NASDAQ
10-K: Ocuphire Pharma Releases 2023 Annual Report, Highlights Progress in Retinal and Refractive Therapies
Ocuphire Pharma's 2023 annual report details the company's progress in developing novel therapies for retinal and refractive eye disorders, including the FDA approval of RYZUMVI and advancements in clinical trials for APX3330 and PS.